Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease
开发减毒呋喃酮作为阿尔茨海默病的新疗法
基本信息
- 批准号:10337296
- 负责人:
- 金额:$ 38.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:3-nitrotyrosine3xTg-AD mouseABCB1 geneAD transgenic miceADME StudyAlzheimer&aposs DiseaseAlzheimer&aposs disease therapyAmyloid beta-42Amyloid beta-ProteinAnimalsAttenuatedBiological AvailabilityBiological MarkersBrainBrain-Derived Neurotrophic FactorCell Culture TechniquesCellsCerebrovascular CirculationClinicalCognitionCyclic AMP-Dependent Protein KinasesCyclic AMP-Responsive DNA-Binding ProteinCyclic GMPCytoprotectionDataDevelopmentDiseaseDoseDrug DesignDrug KineticsElectrophysiology (science)EngineeringExhibitsFailureGlucoseGlutamatesGoalsGrowthHigh Pressure Liquid ChromatographyHippocampus (Brain)HistopathologyHypotensivesImmunohistochemistryIn VitroInfrastructureInstitutesLeadLearningLong-Term PotentiationMAPK3 geneMeasuresMediatingMedicalMemoryMemory LossMemory impairmentMetabolicMetabolismModelingModernizationMolecular AnalysisMolecular StructureMonitorMusNamesNeurodegenerative DisordersNeuronsNitratesNitric OxideOralOxidative StressOxygenPC12 CellsPathway interactionsPenetrationPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPharmacodynamicsPharmacotherapyPhasePhosphorylationPlasmaPrevalenceProductionPropertyProteinsResearchRouteScienceShort-Term MemorySignal TransductionSignaling ProteinSliceSoluble Guanylate CyclaseSulfhydryl CompoundsSurvival RateSynaptic TransmissionSynaptic plasticitySynthesis ChemistrySystemic blood pressureTestingTherapeutic InterventionThioflavin SToxic effectTransgenic MiceTransgenic OrganismsUniversitiesUp-RegulationValidationWestern BlottingWorkacute toxicityanalogbehavioral outcomeblood-brain barrier penetrationcalmodulin-dependent protein kinase IIcholinergiccognitive functioncohortcombatcostdeprivationdesigndrug developmentefficacy studyefficacy validationexperimental studyfear memoryfrontierfuroxansgene productimmunocytochemistryimprovedin vivoinsightintraperitoneallead optimizationmimeticsneuroprotectionneuroregulationneurorestorationnovelnovel therapeuticsoAβpharmacokinetics and pharmacodynamicsprimary outcomescale upscreeningsexside effectsmall moleculesuccesssynaptic functiontargeted treatmenttherapy developmenttranscription factor
项目摘要
Project Summary/Abstract
Significant effort has been put toward developing therapies targeted at amyloid-β peptide (Aβ), the
hallmark toxic aggregatory protein associated with AD. Unfortunately, Aβ targeted therapies have resulted in
several costly Phase III clinical failures. This research focuses on developing novel cognition enhancing
agents which do not directly target Aβ but may reverse the effects of Aβ on cognitive function and provide
neurorestorative effects by up-regulating neurogenic gene products.
Nitric oxide (NO) mimetics activate an intracellular 2nd messenger known as soluble guanylyl cyclase
(sGC) leading to increased cyclic GMP (cGMP) production and increased phosphorylation/activation of
cAMP response element binding protein- CREB (pCREB). CREB phosphorylation is recognized as being a
crucial regulator of synaptic plasticity, resulting in the production of pro-growth gene products, such as brain
derived neurotrophic factor (BDNF), and enhanced synaptic transmission. NO/cGMP/CREB signaling is
disrupted in AD via Aβ-mediated inhibition of NO-induced CREB phosphorylation and synaptic plasticity.
Reversal of Aβ induced memory impairment via agents which activate NO/cGMP signaling results in
improved cognitive function. Hence, NO/cGMP activating agents show potential for the treatment of AD.
Furoxans are a class of thiol-dependent NO mimetics which may hold potential as novel neurorestorative
therapies. Furoxans are distinct because they exhibit `tunable' NO mimetic effects. A unique molecular
structure distinguishes furoxans from classical NO mimetic nitrates and makes it possible to engineer
molecules with significantly reduced rates of NO mimetic activity. HPLC-MS/MS analysis reveals that
furoxan reactivity can be manipulated in a predictable manner to avoid the adverse systemic hypotensive
side-effects associated with transient fluxes of NO. Preliminary studies indicate furoxans have good brain
penetration, neuroprotective activity, and cognition enhancing effects via NO/cGMP/CREB signaling.
This project represents a hit-to-lead optimization campaign for the development of furoxans as novel
agents for AD. Our approach includes- 1) synthesis of novel analogs and preliminary screening in PC12
cells for protection against oxidative stress; 2) Counter screening active analogs in a focused in vitro
pharmacokinetic battery; 3) validating efficacy to improve synaptic function (ex vivo LTP experiments) and
protect primary cortical neurons from Aβ induced toxicity; 4) a focused PK/PD study to define a relationship
between orally administered furoxan, unbound furoxan in the hippocampus, and engagement of NO/cGMP
signaling. A brief dose escalation study will confirm that furoxans do not affect systemic blood pressure or
possess acute toxicity prior to conducting a pilot in vivo efficacy in 3xTg transgenic AD mice. Primary
outcomes focus on the ability to improve spatial working and contextual fear memory in 3xTg mice.
项目摘要/摘要
针对淀粉样蛋白-β肽(A-β)的治疗方法已经投入了大量的努力。
标志着与阿尔茨海默病相关的有毒聚集蛋白。不幸的是,Aβ靶向治疗导致了
几次代价高昂的第三阶段临床失败。这项研究的重点是开发新的认知增强
不直接针对Aβ但可能逆转Aβ对认知功能的影响并提供
上调神经源性基因产物的神经修复作用。
一氧化氮(NO)模拟物激活细胞内第二信使--可溶性鸟苷酸环化酶
(SGC)导致环鸟苷酸(CGMP)产量增加和磷酸化/激活增加
CAMP反应元件结合蛋白-CREB(PCREB)。CREB的磷酸化被认为是一种
突触可塑性的关键调节因子,导致促生长基因产物的产生,如脑
衍生神经营养因子(BDNF)和增强突触传递。NO/cGMP/CREB信号是
通过Aβ介导的抑制NO诱导的CREB磷酸化和突触可塑性在AD中被破坏。
通过激活NO/cGMP信号通路逆转β引起的记忆障碍
改善认知功能。因此,NO/cGMP激动剂具有治疗AD的潜力。
Furoxans是一类硫醇依赖的NO模拟物,有可能成为新的神经修复药物
治疗。Furoxans之所以与众不同,是因为它们没有模拟效果,而且是可调的。一种独特的分子
结构将呋喃黄素与经典的NO模拟硝酸盐区分开来,并使工程设计成为可能
NO模拟活性显著降低的分子。HPLC-MS/MS分析表明,
呋喃沙星的反应性可以通过可预测的方式进行控制,以避免不良的全身性低血压
与NO瞬时通量相关的副作用。初步研究表明呋喃黄素有良好的大脑
通过NO/cGMP/CREB信号通路发挥穿透性、神经保护活性和认知增强作用。
该项目代表了一场针对呋喃黄素开发为新奇的点击到领先的优化运动。
AD的代理。我们的方法包括:1)新类似物的合成和在PC12中的初步筛选
细胞对氧化应激的保护作用;2)体外反筛选活性类似物
药物动力学电池;3)验证改善突触功能的疗效(体外LTP实验)和
保护原代大脑皮层神经元免受β的毒性;4)一项集中的PK/PD研究以确定两者之间的关系
口服呋喃黄生、海马区游离呋喃黄生和NO/cGMP参与之间的关系
发信号。一项简短的剂量递增研究将证实,呋喃黄素不会影响全身血压或
在对3xTg转基因AD小鼠进行体内试验之前具有急性毒性。主要
结果集中在改善3xTg小鼠的空间工作和背景恐惧记忆的能力上。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.
- DOI:10.1016/j.biopha.2021.111437
- 发表时间:2021-06
- 期刊:
- 影响因子:0
- 作者:Creeden JF;Imami AS;Eby HM;Gillman C;Becker KN;Reigle J;Andari E;Pan ZK;O'Donovan SM;McCullumsmith RE;McCullumsmith CB
- 通讯作者:McCullumsmith CB
Subcellular partitioning of protein kinase activity revealed by functional kinome profiling.
- DOI:10.1038/s41598-022-21026-5
- 发表时间:2022-10-15
- 期刊:
- 影响因子:4.6
- 作者:
- 通讯作者:
Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases.
- DOI:10.3390/ijms21228679
- 发表时间:2020-11-17
- 期刊:
- 影响因子:5.6
- 作者:Creeden JF;Alganem K;Imami AS;Brunicardi FC;Liu SH;Shukla R;Tomar T;Naji F;McCullumsmith RE
- 通讯作者:McCullumsmith RE
The active kinome: The modern view of how active protein kinase networks fit in biological research.
- DOI:10.1016/j.coph.2021.11.007
- 发表时间:2022-03
- 期刊:
- 影响因子:4
- 作者:
- 通讯作者:
Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example.
- DOI:10.1038/s41398-021-01724-w
- 发表时间:2021-11-16
- 期刊:
- 影响因子:6.8
- 作者:Imami AS;McCullumsmith RE;O'Donovan SM
- 通讯作者:O'Donovan SM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Isaac T Schiefer其他文献
Isaac T Schiefer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Isaac T Schiefer', 18)}}的其他基金
Cross platform analysis of drug targets and toxicity of bath salts
药物靶点和浴盐毒性的跨平台分析
- 批准号:
10444755 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Cross platform analysis of drug targets and toxicity of bath salts
药物靶点和浴盐毒性的跨平台分析
- 批准号:
10704604 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
相似海外基金
Novel PPAR-gamma agonist selectively activate the ligand binding domain of PPAR-gamma and improve pathology and memory deficits in a 3xTg-Ad mouse model.
新型 PPAR-gamma 激动剂选择性激活 PPAR-gamma 的配体结合域,改善 3xTg-Ad 小鼠模型的病理和记忆缺陷。
- 批准号:
8890576 - 财政年份:2015
- 资助金额:
$ 38.63万 - 项目类别:
Targeting Amyloid Beta Oligomers in the 3xTg-AD Mouse Model with scFv Antibodies
使用 scFv 抗体靶向 3xTg-AD 小鼠模型中的淀粉样蛋白 β 寡聚物
- 批准号:
7407908 - 财政年份:2008
- 资助金额:
$ 38.63万 - 项目类别:














{{item.name}}会员




